TABLE 1.
The application of organic nanoparticle-based drug delivery system.
| Drug | Carrier | Disease | Structure | References |
| SDF- 1α | PLGA | Implant station | Solid scaffold | Thevenot et al., 2010 |
| Ac2-26 | Col IV-targeted PLGA | Atherosclerosis | Nanoparticle | Fredman et al., 2015 |
| DOXY | PLGA | Periodontitis and arthritis | 3D scaffold | Feng et al., 2010 |
| Teicoplanin | mPEG-PLGA | Osteomyelitis | Sol-gel | Peng et al., 2010 |
| ODN | CS-PLGA | Ulcerative colitis | Nanospheres | Tahara et al., 2011 |
| MTX | 177Lu-DOTA-HA-PLGA | Rheumatic arthritis | Nanoparticle | Trujillo-Nolasco et al., 2019 |
| Curcumin | Exosome | Septic shock | Nanoparticle | Sun et al., 2010 |
| Dex | FPC-Exosome | Rheumatic arthritis | Nanoparticle | Yan et al., 2020 |
| NA | TGF-β1-Exosome | Colitis | Nanoparticle | Cai et al., 2012 |
| NA | G-MDSC Exosome | Colitis | Nanoparticle | Wang et al., 2016 |
| HAL | M2 Exosome | Atherosclerosis | Nanoparticle | Wu et al., 2020 |
| IL-10 | Liposome | Obesity | Nanoparticle | Toita et al., 2016 |
| PIO | Liposome | Atherosclerotic plaques | Nanoparticle | Wu et al., 2019b |
| Dex/Mino | Liposome-PEEK | Orthopedic/dental implant | Nanoparticle | Xu et al., 2019 |
Ac2-26, amino acids 2-26; Col IV, collagen IV; CS, chitosan; DOXY, doxycycline; Dex, dexamethasone; Dex/Mino, dexamethasone plus minocycline; FPC, folic acid (FA)-polyethylene glycol (PEG)-cholesterol (Chol); G-MDSC, granulocytic myeloid-derived suppressor cells; HAL, hexyl 5-aminolevulinate hydrochloride; 177Lu-DOTA-HA-PLGA, Lutetium-177-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-hyaluronic acid-poly (lactic-co-glycolic acid); IL-10, Interleukin-10; mPEG, poly (ethylene glycol) monomethyl ether; NA, not available; ODN, oral decoy oligonucleotide; PLGA, Poly (lactic-co-glycolic acid); PIO, pioglitazone; SDF- 1α, stromal cell-derived factor-1α; Sol-gel, solution to hydrogel.